Categories: Research

Speaking on a White House panel discussing President Obama's just-released Bioeconomy Blueprint, UCSF Vice Chancellor for Research Keith Yamamoto, PhD, cited the implantable bioartificial kidney project led by UCSF bioengineer Shuvo Roy, PhD, as a prime example of biomedical collaboration with...

New research support awarded to the UCSF School of Pharmacy by the National Institutes of Health during the 2011 fiscal year included a half-dozen on-going projects by BTS faculty:

For the 32nd consecutive year, the UCSF School of Pharmacy received more research funding from the National Institutes of Health (NIH) than any other pharmacy school in the United States.

UCSF bioengineer Tejal Desai, PhD, will receive the 2012 Paul R. Dawson Biotechnology Award from the American Association of Colleges of Pharmacy (AACP) at the group’s annual meeting in July.

The effort led by UCSF bioengineer Shuvo Roy, PhD, to create an implantable artificial kidney for dialysis patients has been selected as one of the first projects to undergo more timely and collaborative review at the U.S. Food and Drug Administration (FDA).

Computational chemist Brian Shoichet, PhD, a faculty member in the Department of Pharmaceutical Chemistry, UCSF School of Pharmacy, is the new director of the California Institute for Quantitative Biosciences (QB3) at UCSF.

A holy grail of drug discovery is to answer key questions about potential new drugs less by experiments in petri dishes and lab animals and more by faster, cheaper engineering efforts using predictive computer models.

A two-year-old, cross-disciplinary effort to invent new medical devices for children, co-founded by bioengineer Shuvo Roy, PhD, has received a two-year $1 million grant from the U.S. Food and Drug Administration (FDA) to expand its work.

To reduce the risk of toxic drug interactions, UCSF's Kathy Giacomini, PhD, and colleagues are screening thousands of prescription drugs, testing how much they inhibit key proteins in kidney and liver cells that help clear medications from the body.

Passengers who travel on American Airlines from September through October 2011 will learn about the surgically implantable bioartificial kidney being developed at UCSF as a permanent solution to end stage renal disease.